DR30318 / Huadong Medicine, Zhejiang Doer Biologics - LARVOL DELTA

DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy. (PubMed, Cancer Immunol Immunother) - "Furthermore, after incubation with human PBMCs and CLDN18.2 expressing cells, DR30318 induced TDCC activity and the production of interleukin-6 (IL-6) and interferon-gamma (IFN-γ). Notably, DR30318 demonstrated significant tumor suppression effects on gastric cancer xenograft models NUGC4/hCLDN18.2 and pancreatic cancer xenograft model BxPC3/hCLDN18.2 without affecting the body weight of mice."

Journal • Trispecific • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • CRP • IFNG • IL6